Table 2.
Name | Fd or LC chain | % Native | Observed oxidation event(s) | Predicted oxidation event(s) | Number of methionine in chain |
---|---|---|---|---|---|
tocilizumab | Fd | 0 | 1 | 0 | 2 |
trastuzumab | Fd | 44 | 1 | 0 | 2 |
lirilumab | Fd | 4 | 1 | 0 | 3 |
sarilumab | Fd | 0 | 2 | 1 | 3 |
efalizumab | Fd | 3 | 1 | 0 | 3 |
imgatuzumab | Fd | 5 | 1 | 0 | 3 |
vesencumab | Fd | 0 | 2 | 1 | 4 |
gemtuzumab | LC | 34 | 1 | 0 | 1 |
tovetumab | LC | 0 | 2 | 1 | 2 |
ponezumab | LC | 14 | 1 | 0 | 1 |
motavizumab | LC | 52 | 1 | 0 | 2 |